| Literature DB >> 34128848 |
Qiuming Liu1, Weifeng Li, Xiaobo Wu, Liang Xu, Pinghua Hu, Yali Cao.
Abstract
ABSTRACT: Reconstruction of breast defects of patients who underwent mastectomy can be challenging. This study was designed to review a series of 43 breast cancer patients who underwent immediate breast reconstruction (IBR) using the latissimus dorsi myocutaneous flap with/without implants. The demographic characteristics, clinical application feasibility, and the satisfaction rates of the patients were retrospectively collected and evaluated.A total of 43 breast cancer patients who underwent mastectomy between August 2015 and February 2020 were included in the retrospective study. The included patients were subjected to IBR using latissimus dorsi muscular flap (LDMF) with/without implants. The clinical application feasibility and the satisfaction rates of the patients were evaluated.Among these patients, 35 patients underwent nipple-sparing mastectomy and 8 patients underwent skin-sparing mastectomy. Twenty-nine patients underwent IBR using LDMF with implants, and 14 patients underwent IBR using LDMF without implants. Among these patients, 2 patients had partial LDMF necrosis and atrophy, and showed significant shrink of the reconstructed breast. One patient developed seromas, and seromas were improved by active dressing change and sucking out the fluid via the skin using a syringe. Two patients had local skin flap necrosis on the chest, 1 patient had preserved areola and local necrosis of the nipple, and this was healed after dressing change. Based on the Harris method, 27, 9, 5, and 2 cases were evaluated as "excellent," "good," "fair," and "poor," respectively.In the present study, the reconstructed breast has natural shape, good symmetry, and hidden postoperative scars. The aesthetic effect is relatively good, and the use of LDMF may represent an acceptable and valid option for IBR. The success of this procedure depends on the design of the incision, the skill and proficiency of the operation, as well as the correct treatment after surgery.Entities:
Mesh:
Year: 2021 PMID: 34128848 PMCID: PMC8213275 DOI: 10.1097/MD.0000000000026175
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Clinical characteristics of the patients.
| Clinical parameters | Number of patients |
| Tumor grade | |
| 1 | 14 |
| 2 | 16 |
| 3 | 13 |
| Tumor size | |
| <3 cm | 20 |
| ≥3 cm | 23 |
| Lymph node metastasis | |
| Yes | 9 |
| No | 34 |
| Nipple-sparing mastectomies | |
| Yes | 35 |
| No | 8 |
| Implants | |
| Yes | 29 |
| No | 14 |
| Breast cancer types | |
| Luminal A | 9 |
| Luminal B | 19 |
| HER2 positive | 8 |
| Basal-like | 7 |
Figure 1The front and lateral views of the patient who underwent NSM using the LDMF with implants after 6 mo. LDMF, latissimus dorsi myocutaneous flap; NSM, nipple-sparing mastectomy.
Figure 2The front and lateral views of patient who underwent SSM using the LDMF with implants after 6 mo. LDMF, latissimus dorsi myocutaneous flap; SSM, skin-sparing mastectomy.
Figure 3The front and lateral views of the patient who underwent NSM using the LDMF without implants after 6 mo. LDMF, latissimus dorsi myocutaneous flap; NSM, nipple-sparing mastectomy.
Harris score from the included patients.
| Harris score | Number of patients | |
| With implants | Without implants | |
| Excellent | 19 | 8 |
| Good | 5 | 4 |
| Fair | 3 | 2 |
| Poor | 2 | 0 |